Buy Rating Affirmed for Prime Medicine, Inc. on Strong Preclinical Data and Promising Clinical Outlook

TipRanksApr 26 00:35

Prime Medicine Price Target Maintained With a $12.00/Share by Wedbush

Prime Medicine Price Target Maintained With a $12.00/Share by Wedbush

Dow JonesApr 24 01:25

Wedbush: Reiterates Prime Medicine's (PRME.US) rating and adjusted from superior to superior market rating, with a target price of $12.00.

Wedbush: Reiterates Prime Medicine's (PRME.US) rating and adjusted from superior to superior market rating, with a target price of $12.00.

Zhitong FinanceApr 24 01:20

Wedbush Reiterates Outperform on Prime Medicine, Maintains $12 Price Target

Wedbush analyst David Nierengarten reiterates Prime Medicine (NASDAQ:PRME) with a Outperform and maintains $12 price target.

BenzingaApr 24 01:14

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

PDF Version -- Presentations include new preclinical data for PM359, further demonstrating ability of Prime Editors to efficiently, reproducibly and durably correct causative mutation of CGD; on

Prime MedicineApr 23 12:00

Prime Medicine Initiated at Buy by Chardan Capital

Prime Medicine Initiated at Buy by Chardan Capital

Dow JonesApr 22 20:00